The Conversation (0)
Misonix (:NASDAQ:MSON) has announced it has received US Food and Drug Administration (FDA) clearance for Nexus, an ultrasonic surgical platform. As quoted in the press release: Misonix will commence the commercialization of the Nexus platform in the United States in July. Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s …
Misonix (:NASDAQ:MSON) has announced it has received US Food and Drug Administration (FDA) clearance for Nexus, an ultrasonic surgical platform.
As quoted in the press release:
Misonix will commence the commercialization of the Nexus platform in the United States in July.
Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions. The Nexus platform is driven by a new proprietary digital algorithm that results in more power, efficiency and control. Nexus uniquely incorporates RF capabilities, allowing for use in general surgery procedures. The device also incorporates Smart Technology that allows for easier setup and use.
Physicians will be able to utilize Nexus’ increased power to improve tissue resection rates, in concert with its proprietary digital algorithm to perform more efficient bone removal procedures. In addition, Nexus’ ease of use will enable physicians to fully leverage Nexus’ impressive capabilities via its digital touchscreen display and smart system setup.
Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, commented, “We are very pleased to have achieved this critical approval, marking a significant milestone for Misonix and the culmination of years of hard work. Nexus is a powerful, highly integrated and easy-to-use system that will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology allowing for increased efficiency and efficacy, and thus improved outcomes. It is truly a transformational product.
